Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 18:2020:1973241.
doi: 10.1155/2020/1973241. eCollection 2020.

EGFR Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis

Vladimir Jurisic  1 , Vladimir Vukovic  2 , Jasmina Obradovic  3 , Lyudmila F Gulyaeva  4 , Nikolay E Kushlinskii  5 , Nataša Djordjević  6
Affiliations
Review

EGFR Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis

Vladimir Jurisic et al. J Oncol. .

Abstract

Tyrosine kinase inhibitor- (TKI-) based therapy revolutionized the overall survival and the quality of life in non-small-cell lung cancer (NSCLC) patients that have epidermal growth factor receptor (EGFR) mutations. However, EGFR is a highly polymorphic and mutation-prone gene, with over 1200 single nucleotide polymorphisms (SNPs). Since the role of EFGR polymorphism on the treatment outcome is still a matter of debate, this research analyzed the available literature data, according to the PRISMA guidelines for meta-analyses. Research includes PubMed, Scopus, ISI Web of Science, and 14 of genome-wide association studies (GWAS) electronic databases in order to provide quantitative assessment of the association between ten investigated EGFR SNPs and the survival of NSCLC patients. The pooled HR and their 95% CI for OS and PFS for different EGFR polymorphisms using a random or fixed effect model based on the calculated heterogeneity between the studies was applied. The longest and the shortest median OSs were reported for the homozygous wild genotype and a variant allele carriers for rs712829 (-216G>T), respectively. Quantitative synthesis in our study shows that out of ten investigated EGFR SNPs (rs11543848, rs11568315, rs11977388, rs2075102, rs2227983, rs2293347, rs4947492, rs712829, rs712830, and rs7809028), only four, namely, rs712829 (-216G>T), rs11568315 (CA repeat), rs2293347 (D994D), and rs4947492, have been reported to affect the outcome of TKI-based NSCLC treatment. Of these, only -216G>T and variable CA repeat polymorphisms have been confirmed by meta-analysis of available data to significantly affect OS and PFS in gefitinib- or erlotinib-treated NSCLC patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1
Flowchart depicting the literature search and study selection process.
Figure 2
Figure 2
Forest plot reporting pooled HR and their 95% CI of four SNPs for the OS. The square size indicates the weight of each study and of pooled data.
Figure 3
Figure 3
Forest plot reporting pooled HR and their 95% CI of three SNPs for the PFS. The square size indicates the weight of each study and of pooled data.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lu T., Yang X., Huang Y., et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Management and Research. 2019;11:943–953. doi: 10.2147/cmar.s187317. - DOI - PMC - PubMed
    1. Lortet-Tieulent J., Renteria E., Sharp L., et al. Convergence of decreasing male and increasing female incidence rates in major tobacco-related cancers in Europe in 1988–2010. European Journal of Cancer. 2015;51(9):1144–1163. doi: 10.1016/j.ejca.2013.10.014. - DOI - PubMed
    1. Bray F., Ferlay J., Laversanne M., et al. Cancer incidence in five continents: inclusion criteria, highlights from volume X and the global status of cancer registration. International Journal of Cancer. 2015;137(9):2060–2071. doi: 10.1002/ijc.29670. - DOI - PubMed
    1. Ferlay J., Colombet M., Soerjomataram I., et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer. 2019;144(8):1941–1953. doi: 10.1002/ijc.31937. - DOI - PubMed
    1. Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed